Opposing effects of cancer-Type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors

Hana Janouskova; Geniver El Tekle; Elisa Bellini; Namrata D. Udeshi; Anna Rinaldi; Anna Ulbricht; Tiziano Bernasocchi; Gianluca Civenni; Marco Losa; Tanya Svinkina; Craig M. Bielski; Gregory V. Kryukov; Luciano Cascione; Sara Napoli; Radoslav I. Enchev; David G. Mutch; Michael E. Carney; Andrew Berchuck; Boris J.N. Winterhoff; Russell R. Broaddus; Peter Schraml; Holger Moch; Francesco Bertoni; Carlo V. Catapano; Matthias Peter; Steven A. Carr; Levi A. Garraway; Peter J. Wild; Jean Philippe P. Theurillat

doi:10.1038/nm.4372

Opposing effects of cancer-Type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors

Hana Janouskova, Geniver El Tekle, Elisa Bellini, Namrata D. Udeshi, Anna Rinaldi, Anna Ulbricht, Tiziano Bernasocchi, Gianluca Civenni, Marco Losa, Tanya Svinkina, Craig M. Bielski, Gregory V. Kryukov, Luciano Cascione, Sara Napoli, Radoslav I. Enchev, David G. Mutch, Michael E. Carney, Andrew Berchuck, Boris J.N. Winterhoff, Russell R. BroaddusPeter Schraml, Holger Moch, Francesco Bertoni, Carlo V. Catapano, Matthias Peter, Steven A. Carr, Levi A. Garraway, Peter J. Wild, Jean Philippe P. Theurillat

Pathology

Research output: Contribution to journal › Article › peer-review

131 Scopus citations

Abstract

It is generally assumed that recurrent mutations within a given cancer driver gene elicit similar drug responses. Cancer genome studies have identified recurrent but divergent missense mutations affecting the substrate-recognition domain of the ubiquitin ligase adaptor SPOP in endometrial and prostate cancers. The therapeutic implications of these mutations remain incompletely understood. Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-Associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-Associated SPOP mutants. The resulting reduction of BET protein levels sensitized cancer cells to BET inhibitors. Conversely, prostate cancer-specific SPOP mutations resulted in impaired degradation of BETs, promoting their resistance to pharmacologic inhibition. These results uncover an oncogenomics paradox, whereby mutations mapping to the same domain evoke opposing drug susceptibilities. Specifically, we provide a molecular rationale for the use of BET inhibitors to treat patients with endometrial but not prostate cancer who harbor SPOP mutations.

Original language	English (US)
Pages (from-to)	1046-1054
Number of pages	9
Journal	Nature medicine
Volume	23
Issue number	9
DOIs	https://doi.org/10.1038/nm.4372
State	Published - Sep 1 2017

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/nm.4372

Cite this

Janouskova, H., El Tekle, G., Bellini, E., Udeshi, N. D., Rinaldi, A., Ulbricht, A., Bernasocchi, T., Civenni, G., Losa, M., Svinkina, T., Bielski, C. M., Kryukov, G. V., Cascione, L., Napoli, S., Enchev, R. I., Mutch, D. G., Carney, M. E., Berchuck, A., Winterhoff, B. J. N., ... Theurillat, J. P. P. (2017). Opposing effects of cancer-Type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nature medicine, 23(9), 1046-1054. https://doi.org/10.1038/nm.4372

Janouskova, H, El Tekle, G, Bellini, E, Udeshi, ND, Rinaldi, A, Ulbricht, A, Bernasocchi, T, Civenni, G, Losa, M, Svinkina, T, Bielski, CM, Kryukov, GV, Cascione, L, Napoli, S, Enchev, RI, Mutch, DG, Carney, ME, Berchuck, A, Winterhoff, BJN, Broaddus, RR, Schraml, P, Moch, H, Bertoni, F, Catapano, CV, Peter, M, Carr, SA, Garraway, LA, Wild, PJ & Theurillat, JPP 2017, 'Opposing effects of cancer-Type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors', Nature medicine, vol. 23, no. 9, pp. 1046-1054. https://doi.org/10.1038/nm.4372

@article{0f6b621f49c94bbc9f595a582cd05459,

title = "Opposing effects of cancer-Type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors",

abstract = "It is generally assumed that recurrent mutations within a given cancer driver gene elicit similar drug responses. Cancer genome studies have identified recurrent but divergent missense mutations affecting the substrate-recognition domain of the ubiquitin ligase adaptor SPOP in endometrial and prostate cancers. The therapeutic implications of these mutations remain incompletely understood. Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-Associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-Associated SPOP mutants. The resulting reduction of BET protein levels sensitized cancer cells to BET inhibitors. Conversely, prostate cancer-specific SPOP mutations resulted in impaired degradation of BETs, promoting their resistance to pharmacologic inhibition. These results uncover an oncogenomics paradox, whereby mutations mapping to the same domain evoke opposing drug susceptibilities. Specifically, we provide a molecular rationale for the use of BET inhibitors to treat patients with endometrial but not prostate cancer who harbor SPOP mutations.",

author = "Hana Janouskova and {El Tekle}, Geniver and Elisa Bellini and Udeshi, {Namrata D.} and Anna Rinaldi and Anna Ulbricht and Tiziano Bernasocchi and Gianluca Civenni and Marco Losa and Tanya Svinkina and Bielski, {Craig M.} and Kryukov, {Gregory V.} and Luciano Cascione and Sara Napoli and Enchev, {Radoslav I.} and Mutch, {David G.} and Carney, {Michael E.} and Andrew Berchuck and Winterhoff, {Boris J.N.} and Broaddus, {Russell R.} and Peter Schraml and Holger Moch and Francesco Bertoni and Catapano, {Carlo V.} and Matthias Peter and Carr, {Steven A.} and Garraway, {Levi A.} and Wild, {Peter J.} and Theurillat, {Jean Philippe P.}",

year = "2017",

month = sep,

day = "1",

doi = "10.1038/nm.4372",

language = "English (US)",

volume = "23",

pages = "1046--1054",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Opposing effects of cancer-Type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors

AU - Janouskova, Hana

AU - El Tekle, Geniver

AU - Bellini, Elisa

AU - Udeshi, Namrata D.

AU - Rinaldi, Anna

AU - Ulbricht, Anna

AU - Bernasocchi, Tiziano

AU - Civenni, Gianluca

AU - Losa, Marco

AU - Svinkina, Tanya

AU - Bielski, Craig M.

AU - Kryukov, Gregory V.

AU - Cascione, Luciano

AU - Napoli, Sara

AU - Enchev, Radoslav I.

AU - Mutch, David G.

AU - Carney, Michael E.

AU - Berchuck, Andrew

AU - Winterhoff, Boris J.N.

AU - Broaddus, Russell R.

AU - Schraml, Peter

AU - Moch, Holger

AU - Bertoni, Francesco

AU - Catapano, Carlo V.

AU - Peter, Matthias

AU - Carr, Steven A.

AU - Garraway, Levi A.

AU - Wild, Peter J.

AU - Theurillat, Jean Philippe P.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - It is generally assumed that recurrent mutations within a given cancer driver gene elicit similar drug responses. Cancer genome studies have identified recurrent but divergent missense mutations affecting the substrate-recognition domain of the ubiquitin ligase adaptor SPOP in endometrial and prostate cancers. The therapeutic implications of these mutations remain incompletely understood. Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-Associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-Associated SPOP mutants. The resulting reduction of BET protein levels sensitized cancer cells to BET inhibitors. Conversely, prostate cancer-specific SPOP mutations resulted in impaired degradation of BETs, promoting their resistance to pharmacologic inhibition. These results uncover an oncogenomics paradox, whereby mutations mapping to the same domain evoke opposing drug susceptibilities. Specifically, we provide a molecular rationale for the use of BET inhibitors to treat patients with endometrial but not prostate cancer who harbor SPOP mutations.

AB - It is generally assumed that recurrent mutations within a given cancer driver gene elicit similar drug responses. Cancer genome studies have identified recurrent but divergent missense mutations affecting the substrate-recognition domain of the ubiquitin ligase adaptor SPOP in endometrial and prostate cancers. The therapeutic implications of these mutations remain incompletely understood. Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-Associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-Associated SPOP mutants. The resulting reduction of BET protein levels sensitized cancer cells to BET inhibitors. Conversely, prostate cancer-specific SPOP mutations resulted in impaired degradation of BETs, promoting their resistance to pharmacologic inhibition. These results uncover an oncogenomics paradox, whereby mutations mapping to the same domain evoke opposing drug susceptibilities. Specifically, we provide a molecular rationale for the use of BET inhibitors to treat patients with endometrial but not prostate cancer who harbor SPOP mutations.

UR - http://www.scopus.com/inward/record.url?scp=85029058920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029058920&partnerID=8YFLogxK

U2 - 10.1038/nm.4372

DO - 10.1038/nm.4372

M3 - Article

C2 - 28805821

AN - SCOPUS:85029058920

SN - 1078-8956

VL - 23

SP - 1046

EP - 1054

JO - Nature medicine

JF - Nature medicine

IS - 9

ER -

Opposing effects of cancer-Type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this